希瑪眼科(03309.HK)擬900萬港元收購希華檢測90%股權
格隆匯 2 月 9日丨希瑪眼科(03309.HK)宣佈,於2021年2月9日,公司全資附屬公司希瑪檢測擬向林順潮及李肖婷收購希華檢測90%股權,總代價為現金900萬港元。
據悉,希華檢測主要從事提供醫學實驗室服務。其為香港政府認可的本地COVID-19核酸檢測機構之一,並已於2020年12月取得香港認可處(HKAS)的香港實驗所認可計劃(HOKLAS)認證。目前,希華檢測配備有一隻由合資格醫療及實驗室人員組成的團隊,還擁有本身的實驗室設備。希華檢測於取得香港實驗所認可計劃(HOKLAS)認證後,已於2021年1月投入商業運營。緊接收購事項前,希華檢測分別由執行董事兼控股股東林順潮及李肖婷擁有85%及15%權益。
公吿稱,董事會認為,收購事項將與集團現有服務相得益彰,並將提升集團作為綜合醫療服務供應商的醫療服務。董事會認為,收購事項符合集團的發展策略,對集團而言乃屬策略性投資機會。於收購事項後,集團可進一步將希華檢測的服務範圍拓展至其他醫學實驗室檢測服務(包括但不限於眼科)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.